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Abstract
Context: Familial glucocorticoid deﬁciency (FGD) is a rare autosomal recessive disease, characterised by
isolated glucocorticoid deﬁciency in the absence of mineralocorticoid deﬁciency. Inactivating
mutations in the ACTH receptor (melanocortin-2-receptor, MC2R) are well described and account
for w25% of cases. By contrast, activating MC2R mutations are extremely rare.
Patient: We report a child of Saudi Arabian origin who was diagnosed with FGD following
hypoglycaemic episodes that resulted in spastic quadriplegia.
Methods and results: MC2R gene analysis revealed an unusual combination of two homozygous
missense mutations, consisting of the novel mutation Y129C and the previously described F278C
activating mutation. Parents were heterozygous at both of these sites. In vitro analysis of the Y129C
mutation using a ﬂuorescent cell surface assay showed that this mutant was unable to reach the cell
surface in CHO cells stably transfected with MC2R accessory protein (MRAP), despite the
demonstration of an interaction with MRAP by co-immunoprecipitation. The double mutant
Y129C-F278C also failed to trafﬁc to the cell surface.
Conclusion: The tyrosine residue at position 129 in the second intracellular loop is critical in MC2R
folding and/or trafﬁcking to the cell surface. Furthermore, the absence of cell surface expression of
MC2R would account for the lack of activation of the receptor due to the F278C mutation located at
the C-terminal tail. We provide a novel molecular explanation for a child with two opposing mutations
causing severe FGD.
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Introduction
Familial glucocorticoid deﬁciency (FGD) (OMIM
202200) is a rare autosomal recessive condition
clinically characterised by isolated glucocorticoid deﬁci-
ency in the presence of normal mineralocorticoid
production (1, 2). Affected individuals usually present
during the neonatal period or by early childhood with
symptoms resulting from either hypocortisolaemia or
elevated plasma ACTH levels. Symptoms include
hypoglycaemic seizures, hyperpigmenation, recurrent
infections, failure to thrive, collapse and coma (2).
Severe long term neurological consequences have been
described, which may reﬂect the severity and number of
hypoglycaemic episodes during childhood. Severe loss-
of-function ACTH receptor/melanocortin-2-receptor
(MC2R) mutations have, however, been associated
with mild derangements in the renin–angiotensin–
aldosterone axis (3).
Inactivating mutations of the MC2Ras a cause of FGD
were ﬁrst described in 1993 (4, 5). Many more
inactivating mutations were subsequently found,
accounting for w25% of FGD cases. The majority of
these are summarised in (2). A further 15–20% of FGD
cases are due to mutations in MC2R accessory protein
(MRAP), which is required for the trafﬁcking and cell
surface expression of the MC2R (6). More recently, a
patient with FGD was reported to have compound
heterozygosity of a frameshift mutation in the coding
region and a single-base substitution in the promoter of
the ACTH receptor (7).
MC2R, the second of the melanocortin receptor
family to be cloned (8), is highly conserved across
species (9) and is distinct from the other four
melanocortin receptors, responding only to its speciﬁc
ligand, ACTH. Several groups have hypothesised that
the MC2R could be involved in ACTH-independent
causes of cortisol excess such as adrenal hyperplasia or
neoplastic conditions. Studies on adrenocortical adeno-
mas and neoplasias failed to identify mutations in the
MC2R (10, 11). However, there is evidence that the
MC2R mRNA expression is increased in aldosterone and
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heterozygosity of the MC2R locus has been demon-
strated in adrenocortical tumours (14).
The ﬁrst and so far onlyactivating homozygous germ-
line MC2R mutation causing glucocorticoid excess was
found in a patient with cyclical Cushing’s syndrome
(15). The missense mutation, resulting in the sub-
stitution of a phenylalanine residue by a cysteine at
position 278 (F278C) in the C-terminal tail, was
functionally characterised by Swords et al. (15).
A combination of cAMP accumulation, ACTH
competitive binding and receptor internalisation assays
were used to show that the F278C mutant receptor was
at the cell surface and exhibited increased basal activity
behaving as a receptor with constitutive activity. The
constitutive activityof the mutant receptor was thought
to result from impaired receptor desensitisation (15).
A second cause of increased receptor basal activity
was described in a patient with two mutations (C21R
and S247G) on the same allele of the MC2R that had
synergistic activity resulting in a syndrome of ACTH
hypersensitivity (16, 17).
Subject and methods
Patient report
The index case is the youngest of three children born to
ﬁrst cousins of Saudi Arabian origin. Born at term with
normal birth weight, he presented with hypoglycaemia,
apnoea and cyanosis within the ﬁrst 24 hours of life. He
was diagnosed with pneumonia and sepsis and treated
with antibiotics. At 3 months of age, he presented with
recurrent cough and shortness of breath, and was
treated for a chest infection. He subsequently presented
with collapse,bradycardia and hypotension at 8 months
of age, requiring resuscitation and admission to
intensive care. He was found to be hypoglycaemic and
developed seizures. Investigations revealed a low serum
cortisol and grossly elevated plasma ACTH level (O
1250 pg/ml; N.R. 10–46). Serum electrolytes and
aldosterone levels were normal. He was diagnosed
with adrenal insufﬁciency and initiated on hydrocorti-
sone (HC) replacement. He suffered further seizures and
developed spastic quadriplegia, visual impairment and
neurosensory deafness. An older sibling died at the age
of 7 months after developing seizures post-vaccinations.
She was described as having a dark complexion similar
to the index child. At 1.3 years of age the index child
was reassessed while on HC. His height and weight were
b e t w e e n1 0a n d2 5 t hp e r c e n t i l e ,w h i l eh i sh e a d
circumference was on the 0.4th centile. He was noted
to be darkly pigmented despite replacement with HC
dosage of 20 mg/m
2 per day, a common feature of FGD
(2). This correlated to an extremely high plasma ACTH
level of 1169 ng/l (N.R. 0–50), aldosterone and renin
levels were normal (aldosterone 251 pmol/l
(N.R. recumbent !440); plasma renin activity
38.9 ng/l (recumbent 43–61)). Serum electrolytes and
glucose was normal. A diagnosis of FGD was suspected
and a molecular diagnosis was sought.
Mutational analysis of MC2R
Genomic DNA was extracted from blood leukocytes.
PCR of the single coding exon was performed using
speciﬁc intronic primers (F, 50-AGTCCAAGTAA-
CATCCCC-30,R ,5 0-CCATGGATTCTAAAACCAGGG-30).
After the initial denaturing step at 95 8C for 5 min, a
touchdown program was used i.e. 16 cycles of 95 8C for
30 s, x 8C for 30 s and 72 8C for 1 min (where x was
65 8C for the ﬁrst cycle which then decreased by 1 8C
with each cycle). This was followed by 25 cycles of 95 8C
for 30 s, 45 8C for 30 s and 72 8C for 1 min, with a ﬁnal
extension step at 72 8C for 5 min. PCR products were
sequenced using the ABI Prism Big Dye Sequencing kit
and an ABI 377 automated DNA sequencer (Applied
Biosystems, Foster City, CA, USA) in accordance with
the manufacturer’s instructions.
MC2R expression vectors and MRAP
stable cell line generation
The human MC2R triple HA tagged (3xHA-MC2R)
cDNA clone was obtained from the Missouri S&T cDNA
Resource Center (www.cdna.org). 3xHA-Y129C and
3xHA-F278C single MC2R mutants, in addition to
3xHA-Y129C-F278C double mutant MC2Rwere gener-
ated using the Quick Change site-directed mutagenesis
protocol (Stratagene, Amsterdam, The Netherlands).
Oligonucleotide primers are available on request.
Mutagenesis was conﬁrmed by DNA sequencing. The
full length human MRAPa cDNA was cloned into
pcDNA3.1 (Invitrogen). CHO cells were grown in
DMEM/F12 (1:1 ratio) with 10% FCS and 1%
penicillin/streptomycin mix. Cells were transfected
with MRAPa construct using Lipofectamine 200
(Invitrogen) and selected in 700 mg/ml Genetecin
(G418) (Life Sciences, Paisley, UK). Colonies were
selected after serial dilutions. Selected clones were
screened by RT-PCR to ensure adequate expression of
MRAPa mRNA. Transient transfection of wild-type
(WT) 3xHA-MC2R was performed to ensure surface
expression of the receptor. Cells stably transfected with
pcDNA3.1 alone were used as a negative control.
Western blot and co-immunoprecipitation
(Co-IP)
The interaction between MRAP and mutant MC2R was
assessed by Co-IP using a FLAG-tagged MRAP
construct and 3xHA-Y129C mutant receptor. Cells
were transiently transfected with the vector(s), MRAP-
FLAG, WT 3xHA-MC2R alone or in combination as
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Y129C receptor. For 24 h post-transfection, cells were
scraped into lysis buffer (1% DM in PBS, with protease
inhibitor cocktail 1:1000) and incubated on ice for
30 min before centrifugation at 19 000 g for 30 min at
4 8C. Overnight immunoprecipitation was performed
using anti-HA agarose (Sigma–Aldrich Corp). Western
blotting was performed using anti-FLAG antibodies
(Sigma–Aldrich Corp.) at a dilution of 1 in 2000.
Fluorescent cell surface assay and confocal
microscopy
MRAPa stable cells were grown in 24-well plates and
transfected with WT 3xHA-MC2R, 3xHA-Y129C,
3xHA-F278C or 3xHA-Y129C-F278C construct. For
24 h post-transfection; cells were washed and ﬁxed in
3.7% paraformaldehyde (10 min). Duplicate transfec-
tions were performed on a separate plate. Cells from one
plate were permeabilised with PBS/0.05% Triton-X100.
Both plates were then washed in PBS, blocked in the
LI-COR Odyssey Blocking Buffer for 1 h, and exposed
to primary anti-HA antibody (Sigma–Aldrich Corp.)
for 1 h. Antibody dilution of 1/1000 was used to detect
3xHA-MC2R surface expression in non-permeabilised
cells and total MC2R expression in permeabilised cells.
After 3 washes in PBS, incubation with the secondary
antibody (IRDye 800CW Goat Anti-Mouse IgG; LI-COR,
Lincoln, NE, USA) was undertaken at a concentration of
1/1000 for 1 h. Three further PBS washes followed and
the total ﬂuorescence from each well was measured
using the Odyssey Imaging System (LI-COR). Confocal
microscopy was performed as described in (6).
Statistical analysis
Experiments were performed in duplicate, and the
results represent the mean of three independent
experiments (with the exception of 3xHA-F278C;
nZ2). Statistical signiﬁcance was determined using a
non-paired two-tailed Student’s t-test.
Results
MC2R mutations
DNA analysis of the index child revealed two
homozygous missense mutations. The ﬁrst of these is a
novel homozygous mutation of an A to G nucleotide
substitution resulting in the Y129C change (sub-
stitution of the tyrosine residue with a cysteine at
position 129). The second mutation, also A to G, is the
previously described F278C activating mutation (sub-
stituting the phenylalanine at position 278 with a
cysteine residue). Both these mutations were found in
the homozygous state in the index child (Fig. 1) and in
heterozygosity in both parents. In order for the child to
inherit both mutations in a homozygous state, the two
mutations in the parents must be located on the same
allele.
Y129C single mutant fails to trafﬁc to the
cell surface and is intracellularly retained,
despite interacting with MRAP:
Y129C-F278C double mutant also
fails to trafﬁc to the cell surface
The transient transfection of WT 3xHA-MC2R into
MRAPa stably transfected CHO cells enable efﬁcient
surface expression of the receptor in this heterologous
cell line. The 3xHA-F278C mutant receptor trafﬁcs
efﬁciently to the cell surface. By contrast, the 3xHA-
Y129C and 3xHA-Y129C-F278C mutants fail to trafﬁc
to the plasma membrane in the presence of MRAP
(Fig. 2). Confocal imaging shows surface localisation of
the F278C mutant receptor but intracellular retention
of the Y129C and Y129C-F278C double mutant
protein. The images of the intracellular distribution of
these retained receptors are comparable with those of
the WT 3xHA-MC2R in the absence of MRAP. To assess
whether the substitution of the tyrosine residue at
position 129 affects the interaction with MRAP, a Co-IP
technique was employed. Using CHO cells transiently
co-transfected with 3xHA-Y129C and MRAP-FLAG,
immunoprecipitation of mutant Y129C using anti-HA,
Figure 1 (A) Family tree and mutational analysis of the MC2R.
Partial sequence of the MC2R showing the Y129C mutation and
F278C mutation in heterozygosity in the parents and homozygosity
in index case (ﬁlled box). (B) Pseudostructural plot of the MC2R
showing the location of Y129C in the second intracellular loop and
F278C* in the C-terminal tail. Full colour version of this ﬁgure
available via http://dx.doi.org/10.1530/EJE-08-0636.
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western blotting with an anti-FLAG antibody. This
demonstrated that the ability of the mutant to interact
with MRAP is unaffected by the substitution of the
tyrosine residue. The Y129C trafﬁcking was one of the
mutations studied as part of a larger study (21).
Discussion
The clinical case presented in this report is unique in
that the DNA analysis conﬁrms the presence of two
MC2R mutations that have opposite effects. One of these
mutations (F278C mutation) was previously studied in
Figure 2 (A) Failed surface localisation of the Y129C single mutant receptor and Y129C-F278C double mutant receptor in MRAP
expressing cell lines. In comparison, WT MC2R and F278C mutation trafﬁcs efﬁciently to the plasma membrane in the presence of MRAP.
Fluorescent cell surface assay performed in duplicate in three independent experiments (with the exception of F278C experiments, nZ2).
Values on y-axis represent ﬂuorescent count normalised for total cell number. Error bars represent S.E.M.* P!0.05, **P!0.01. Surface
expression of Y129C was included as part of a larger study (21) (B) Confocal images to show the intracellular retention of the 3xHA-Y129C
and Y129C-F278C mutantin MRAPstable cell lines.This is similar toWT 3xHA-MC2R retentionseenin the absence of MRAP. Bycontrast,
the WT 3xHA-MC2R and 3xHA-F278C in the presence of MRAP localises to the cell surface efﬁciently. Size bar represents 10 mm. (C)
Co-immunoprecipitation of MRAP-FLAG and HA tagged receptor show direct interaction between MRAP and Y129C receptor as well as
WT MC2R. MRAP – FLAG band indicated by (3). IP, immunoprecipitation; IB, immunoblotting, *light chain, **heavy chain. Full colour
version of this ﬁgure available via http://dx.doi.org/10.1530/EJE-08-0636.
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activity. Speciﬁcally, surface expression of F278C
mutant receptor was demonstrated by [125] ACTH
binding assays (15). This was conﬁrmed in our present
study by immunoﬂuorescent cell surface assay and
confocal microscopy.
We therefore assessed the second mutation, a novel
inactivating missense mutation, Y129C, located in the
second intracellular loop in isolation and with the
F278C mutation. We hypothesised that the Y129C
mutation may affect cell surface expression of MC2R,
which would provide an explanation for the apparent
lack of activation secondary to the F278C mutation. We
tested this hypothesis by studying the ability of the
Y129C receptor to trafﬁc to the cell surface, using a
ﬂuorescent cell surface assay. Transfection of the Y129C
single and double mutant MC2R into CHO cells stably
transfected with MRAP revealed that the Y129C
mutant fails to reach the cell surface, despite its
interaction with MRAP.
The tyrosine residue at position 129 lies in the DRY
motif of the second intracellular loop. This motif is
highly conserved in the entire rhodopsin subclass of
G-protein coupled receptors (18, 19). Our data suggests
that Y129 plays a vital role in folding or cell-surface
trafﬁcking of the receptor. Interestingly, functional
analysis of the neighbouring amino acid R128C
showed that this mutant trafﬁcs to the cell surface
but fails to signal through loss of high-afﬁnity binding
(20, 21).
The index case was severely affected with spastic
quadriplegia. Clinical severity may not always correlate
with genotype. In the MC2R knockout mouse model,
there is great variability in presentation, despite
identical genotype and genetic background some mice
died soon after birth while others were able to survive
into adulthood (22).
In conclusion, we describe a child with two
functionally opposing MC2R mutations. The inability
of the Y129C mutant receptor to localise to the
cell surface in this child essentially inactivates the
ability of the F278C mutation to cause constitutive
activity and a Cushing’s syndrome phenotype, thus
providing a unique molecular explanation for the
existence of two opposing MC2R mutations resulting
in FGD.
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